CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 107 enrolled / 107 target
Drug / intervention
Acalabrutinib (ACP-196) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02180724
NCT02180724Phase 2ActiveUpdate Overdue (0.8/mo)Completion was 81mo ago
CompareCT.gov

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

Acerta Pharma BV·interventional·Posted Jul 3, 2014·Updated Jun 16, 2026

In Brief

A Phase 2 clinical trial evaluating Acalabrutinib (ACP-196) for Waldenström Macroglobulinemia (WM). Active but no longer recruiting, targeting 107 participants across 38 sites in 7 countries.

Signals

Enrollment appears stalled

Detailed Summary

The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and activity of acalabrutinib in treating subjects with WM.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWaldenström Macroglobulinemia (WM)
CountriesFrance, Greece, Italy, Netherlands, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 2Active
2015201620172018201920202021202220232024202520262027
First PostedJul 3, 2014
Enrollment StartSep 11, 2014
Primary CompletionOct 1, 2019
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 12.0 years ago

Arms & Interventions

Previously Treatedexperimental

Subjects previously treated with Waldenström Macroglobulinemia N=92

Drug: Acalabrutinib (ACP-196)
Treatment Naïveexperimental

Subjects with treatment-naïve Waldenström Macroglobulinemia. N=14

Drug: Acalabrutinib (ACP-196)

Interventions

Acalabrutinib (ACP-196)drug

Acalabrutinib (ACP-196)drug